<![CDATA[Abstract: Cervical cancer is a malignancy in the cervix. Chemotherapy is a therapy to kills cancer cells. The side effect of chemotherapy is myelosuppression which results in decreased platelet production. The purpose of study is to determine the description of platelets amount in cervical cancer patients who received paclitaxel and carboplatin chemotherapy phase I, II, III and IV at RSUD Ulin Banjarmasin. This study is descriptive by taking medical records data of cervical cancer patients at RSUD Ulin Banjarmasin period August 2018 - March 2019. The study obtained by 46 patients with cervical cancer included in the criteria. There are 1 patient (2,2%) stage IB and 45 patients (97,8%) stage IIIB. Platelet amount are 100% normal in phase I, II, III and IV stage IB cervical cancer patients. In stage IIIB, 14 patients (31,1%) increased and no decreased before chemotherapy. One patient (2,2%) decreased and nine patients (20%) increased after the first chemotherapy. Three patients (6,7%) decreased and four patients (8.9%) increased after the second chemotherapy. Five patients (11,1%) decreased and three patients (6,7%) increased after the third chemotherapy. Seven patients (15,6%) decreased and five patients (11,1%) increased after the fourth chemotherapy. Keywords: cervical cancer, platelet amount, chemotherapy Abstrak: Kanker serviks yaitu keganasan di leher rahim. Kemoterapi adalah terapi untuk menghancurkan sel kanker. Efek samping kemoterapi yaitu mielosupresi yang mengakibatkan terjadinya penurunan produksi trombosit. Tujuan penelitian ini untuk mengetahui gambaran jumlah trombosit pada pasien kanker serviks yang menerima kemoterapi paklitaksel dan karboplatin fase I, II, III dan IV di RSUD Ulin Banjarmasin. Penelitian ini bersifat deskriptif dengan pengambilan data rekam medik pasien kanker serviks di RSUD Ulin Banjarmasin periode Agustus 2018 – Maret 2019. Hasil penelitian diperoleh 46 pasien kanker serviks yang memenuhi kriteria. Terdapat 1 pasien (2,2%) stadium IB dan 45 pasien (97,8%) stadium IIIB. Jumlah trombosit 100 % normal pada pasien kanker serviks stadium IB fase I, II, III dan IV. Pada stadium IIIB, didapatkan 14 pasien (31,1%) meningkat dan tidak ada yang menurun sebelum kemoterapi. Sebanyak 1 pasien (2,2%) menurun dan 9 pasien (20%) meningkat sesudah kemoterapi pertama. Sebanyak 3 pasien (6,7%) menurun dan 4 pasien (8,9%) meningkat sesudah kemoterapi kedua. Sebanyak 5 pasien (11,1%) menurun dan 3 pasien (6,7%) meningkat sesudah kemoterapi ketiga. Sebanyak 7 pasien (15,6%) menurun dan 5 pasien (11,1%) meningkat sesudah kemoterapi keempat. Kata-kata kunci: Kanker serviks, jumlah trombosit, kemoterapi]]>
